{"log_id": 4376440463096373399, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0.010425, "average": 0.968121, "min": 0.368003}, "location": {"width": 835, "top": 108, "height": 66, "left": 176}, "words": "本品与食物同时服用时,阿比特龙全身暴露量升高。本品与低脂餐7%脂肪:300卡路里)"}, {"probability": {"variance": 0.00498, "average": 0.970741, "min": 0.640499}, "location": {"width": 851, "top": 157, "height": 66, "left": 136}, "words": "同时服用时;阿比特龙Cm和AUCo分别增加至7倍和5倍左右;本品与高脂餐(57%脂肪"}, {"probability": {"variance": 0.013582, "average": 0.956053, "min": 0.404781}, "location": {"width": 860, "top": 204, "height": 67, "left": 141}, "words": "85卡路)同时服用时,这些值分别增加至17倍和10倍左右鉴于食物的多样性和可变性"}, {"probability": {"variance": 0.014862, "average": 0.952319, "min": 0.388468}, "location": {"width": 870, "top": 251, "height": 69, "left": 139}, "words": "本品与食物同时服用可能会导致暴露量升高易变。故至少在服药前2小时内和服药后1小时"}, {"probability": {"variance": 0.004084, "average": 0.971736, "min": 0.70654}, "location": {"width": 527, "top": 314, "height": 51, "left": 142}, "words": "内不能进食。另外,须用水整片送服本品(见用法用量)"}, {"probability": {"variance": 6e-06, "average": 0.997238, "min": 0.993675}, "location": {"width": 156, "top": 408, "height": 36, "left": 143}, "words": "分布和蛋白结合"}, {"probability": {"variance": 0.011503, "average": 0.961818, "min": 0.47483}, "location": {"width": 829, "top": 427, "height": 62, "left": 189}, "words": "阿比特龙与人血浆蛋白、白蛋白和α1酸性糖蛋白高度结合(99%。稳态表观分布容积"}, {"probability": {"variance": 0.026942, "average": 0.920456, "min": 0.377506}, "location": {"width": 864, "top": 472, "height": 66, "left": 157}, "words": "(均数王D)为19669±13358L。体外研究显示在临床相关浓度范围下:本品和阿比龙均不是"}, {"probability": {"variance": 0.01018, "average": 0.963133, "min": 0.526733}, "location": {"width": 726, "top": 525, "height": 58, "left": 148}, "words": "P糖蛋白的底物,而本品是P-糖蛋白的抑制剂。尚未对其他转运蛋白进行研究"}, {"probability": {"variance": 0, "average": 0.999894, "min": 0.999827}, "location": {"width": 44, "top": 630, "height": 25, "left": 156}, "words": "代谢"}, {"probability": {"variance": 0.017928, "average": 0.943488, "min": 0.385857}, "location": {"width": 827, "top": 643, "height": 60, "left": 200}, "words": "口服c-醋酸阿比特龙胶囊后,醋酸阿比特龙被水解成阿比特龙(活性代谢物)。此过程可"}, {"probability": {"variance": 0.009399, "average": 0.965713, "min": 0.491844}, "location": {"width": 873, "top": 689, "height": 63, "left": 157}, "words": "能是在酯酶(尚未鉴别酸)作用下转化,而不是由YP介导。阿比特龙在人血浆中的两个主"}, {"probability": {"variance": 0.013441, "average": 0.951932, "min": 0.401891}, "location": {"width": 871, "top": 734, "height": 63, "left": 157}, "words": "要循环代谢物为硫酸阿比特龙《无活性)和氧化硫酸阿比特龙(无活性2,各占露量的43%"}, {"probability": {"variance": 0.002816, "average": 0.973366, "min": 0.705999}, "location": {"width": 871, "top": 780, "height": 64, "left": 162}, "words": "左右CYP3A4和SULT2A1参与N氧化硫酸阿比特龙形成,且SUT2A1也参与硫酸阿比特龙形"}, {"probability": {"variance": 0, "average": 0.978809, "min": 0.978809}, "location": {"width": 25, "top": 862, "height": 24, "left": 164}, "words": "成"}, {"probability": {"variance": 1e-06, "average": 0.998356, "min": 0.997377}, "location": {"width": 47, "top": 935, "height": 27, "left": 166}, "words": "排泄"}, {"probability": {"variance": 0, "average": 0.954807, "min": 0.954807}, "location": {"width": 106, "top": 917, "height": 39, "left": 779}, "words": "医"}, {"probability": {"variance": 0.012894, "average": 0.943731, "min": 0.49767}, "location": {"width": 832, "top": 947, "height": 65, "left": 209}, "words": "在 MCRPC患者中,阿比特龙在血浆中的平均终末半衰期均数士SD为15小时。口服"}, {"probability": {"variance": 0.014243, "average": 0.955118, "min": 0.350116}, "location": {"width": 870, "top": 994, "height": 63, "left": 174}, "words": "c-醋酸阿比特龙后从粪便和尿液中分别回收约882%和5%放射性剂量。粪便中存在的主要化"}, {"probability": {"variance": 0.002906, "average": 0.980892, "min": 0.705356}, "location": {"width": 605, "top": 1049, "height": 58, "left": 171}, "words": "合物为本品原形和阿比特龙(分别为给药剂量的55%和22%"}, {"probability": {"variance": 0.00702, "average": 0.948928, "min": 0.766062}, "location": {"width": 155, "top": 1143, "height": 36, "left": 174}, "words": "肝功能损害患者"}, {"probability": {"variance": 0.018219, "average": 0.92153, "min": 0.510159}, "location": {"width": 883, "top": 1162, "height": 61, "left": 221}, "words": "在基线轻度(n=8)或中度n=8美肝功能损害(分别为Chid-PgA和B级受试者和"}, {"probability": {"variance": 0.000457, "average": 0.989392, "min": 0.895182}, "location": {"width": 942, "top": 1194, "height": 80, "left": 176}, "words": "8例肝功能正常的健康受试者中,评估了阿比特龙的药代动力学。基线轻度和中度肝功能损害"}, {"probability": {"variance": 0.01842, "average": 0.937733, "min": 0.519342}, "location": {"width": 871, "top": 1261, "height": 58, "left": 182}, "words": "受试者空腹单次口服1000mg后,阿比特龙的全身暴露量分别增加约1.1倍和36倍。在轻度"}, {"probability": {"variance": 0.002838, "average": 0.986174, "min": 0.657129}, "location": {"width": 873, "top": 1307, "height": 58, "left": 183}, "words": "和中度肝功能损害受试者中,阿比特龙的平均半衰期分别延长至18和19小时。尚未在基线严"}, {"probability": {"variance": 0.020969, "average": 0.927868, "min": 0.513629}, "location": {"width": 717, "top": 1359, "height": 50, "left": 185}, "words": "重肝功能损害( child-pugh C级)患者中研究本品(见用法用量和注意事项)"}, {"probability": {"variance": 0.005474, "average": 0.971143, "min": 0.603907}, "location": {"width": 829, "top": 1399, "height": 55, "left": 230}, "words": "另一项试验在8例基线有严重肝功能损( child-pugh C级)的受试者和8例肝功能正常的"}, {"probability": {"variance": 0.004303, "average": 0.984228, "min": 0.573152}, "location": {"width": 875, "top": 1445, "height": 57, "left": 187}, "words": "健康受试者中分析了阿比特龙的药代动力学。与肝功能正常的受试者相比,基线有严重肝功能"}], "language": 3}